These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33496752)

  • 1. Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
    Nishiwaki S; Akahoshi Y; Mizuta S; Shinohara A; Hirabayashi S; Noguchi Y; Fukuda T; Uchida N; Tanaka M; Onizuka M; Ozawa Y; Ota S; Shiratori S; Onishi Y; Kanda Y; Sawa M; Tanaka J; Atsuta Y; Kako S
    Blood Adv; 2021 Jan; 5(2):584-592. PubMed ID: 33496752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
    Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
    Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.
    Kaito S; Kurosawa S; Najima Y; Sakaida E; Shingai N; Fukuda T; Tachibana T; Uchida N; Ozawa Y; Sawa M; Nakazawa H; Ota S; Kato J; Nakamae H; Katayama Y; Eto T; Tanaka J; Kanda Y; Atsuta Y; Arai Y; Kako S;
    Transplant Cell Ther; 2022 Jun; 28(6):326.e1-326.e10. PubMed ID: 35306218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience.
    Jamieson CH; Amylon MD; Wong RM; Blume KG
    Exp Hematol; 2003 Oct; 31(10):981-6. PubMed ID: 14550815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.
    Nishiwaki S; Imai K; Mizuta S; Kanamori H; Ohashi K; Fukuda T; Onishi Y; Takahashi S; Uchida N; Eto T; Nakamae H; Yujiri T; Mori S; Nagamura-Inoue T; Suzuki R; Atsuta Y; Tanaka J
    Bone Marrow Transplant; 2016 Jan; 51(1):43-50. PubMed ID: 26389833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
    Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
    Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
    Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
    Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Yanada M; Konuma T; Yamasaki S; Mizuno S; Hirabayashi S; Nishiwaki S; Uchida N; Doki N; Tanaka M; Ozawa Y; Sawa M; Eto T; Kawakita T; Ota S; Fukuda T; Onizuka M; Kimura T; Atsuta Y; Kako S; Yano S
    Ann Hematol; 2021 Dec; 100(12):3017-3027. PubMed ID: 34477952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
    Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
    Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
    Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
    Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
    Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
    Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
    Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
    Ribera JM; Morgades M; Ciudad J; Montesinos P; Esteve J; Genescà E; Barba P; Ribera J; García-Cadenas I; Moreno MJ; Martínez-Carballeira D; Torrent A; Martínez-Sánchez P; Monsalvo S; Gil C; Tormo M; Artola MT; Cervera M; González-Campos J; Rodríguez C; Bermúdez A; Novo A; Soria B; Coll R; Amigo ML; López-Martínez A; Fernández-Martín R; Serrano J; Mercadal S; Cladera A; Giménez-Conca A; Peñarrubia MJ; Abella E; Vall-Llovera F; Hernández-Rivas JM; Garcia-Guiñon A; Bergua JM; de Rueda B; Sánchez-Sánchez MJ; Serrano A; Calbacho M; Alonso N; Méndez-Sánchez JÁ; García-Boyero R; Olivares M; Barrena S; Zamora L; Granada I; Lhermitte L; Feliu E; Orfao A
    Blood; 2021 Apr; 137(14):1879-1894. PubMed ID: 33150388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.